Overview
Status
Active
Registry date
2018-07-19
Share capital
5 000,00 PLN
Financials
Only balance sheet data (assets and liabilities) is available. The income statement (P&L) is not available in the source filing for this period.
Revenue history (in k)
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 224 days for 2021).
- 202508/07/2026
- 202419/12/2025
- 202311/02/2025
- 202210/08/2023
- 202124/02/2023
- 202022/09/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Adrian Lis – Management Board Member
Mariusz Mauch – Management Board Member
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Adrian Lisage 36 | 50 | $675.31 | 50% |
Mariusz Mauchage 46 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-09-01.
No bank accounts reported to the VAT Taxpayer Register.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 8, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Olsztyn |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Dystrybucji Farmaceutycznej Slawexsp. z o.o. | $600,815,720.02 | slawex.com.pl | ||
| Hammermed Medical PolskaS.K.A. | $93,061,305.58 | hammer.pl | ||
| BaylegS.A. | $86,155,489.09 | bayleg.pl | ||
| OwlieS.A. | $17,199,251.89 | owlie.pl | ||
| Eclipse Boluk-Sobolewskasp. k. | $10,235,697.61 | eclipsemedical.pl | ||
| BL Medicasp. z o.o. + limited partnership | $886,794.58 | blmedica.pl | ||
| BL Medicasp. z o.o. | $148,305.98 | blmedica.pl | ||
| Pharmbiopolsp. z o.o. | $99,211.10 | pharmbiopol.com | ||
| GROW Pharmasp. z o.o. | $15,020.86 | growpharma.pl | ||
| Medical ExpertS.A. | $0.00 | medicalexpert.com.pl |
FAQ
The main business activity of Swisspharm focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on July 19, 2018.
The headquarters is located at: ul. Jagiellońska 46, 10-273 Olsztyn.
The management board consists of: Adrian Lis (Member of the Management Board) and Mariusz Mauch (Member of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $20, representing a decrease of 99.7% compared to 2023.
No, the company recorded a net loss of $5 in 2024. For comparison, in 2023 the loss was $117, meaning the company reduced its loss by 96.1%.
The largest operating cost category falls under external services. This category amounted to $25 in 2024, representing 100% of all operating expenses.
Last updated: 2026-07-15